Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis
Jennifer A. Kanakry(National Institutes of Health), Richard F. Ambinder(Johns Hopkins University), Heather J. Symons(Johns Hopkins University), Leo Luznik(Johns Hopkins University), Huzefa J. Mogri(Johns Hopkins University), Christopher D. Gocke, William Matsui(The University of Texas at Austin), Ivan Borrello(Tampa General Hospital), Richard J. Jones(Sidney Kimmel Comprehensive Cancer Center), Yvette L. Kasamon(Johns Hopkins University), Ephraim J. Fuchs(Johns Hopkins University), Nilanjan Ghosh(Levine Cancer Institute), Christopher G. Kanakry(National Cancer Institute), Robert A. Brodsky(Johns Hopkins University), Carol Ann Huff(Sidney Kimmel Comprehensive Cancer Center), Douglas E. Gladstone(Northwell Health), Lode J. Swinnen(Johns Hopkins University), Javier Bolaños‐Meade(Johns Hopkins University)
Cited by 114
Related Papers
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k